Jefferies Financial Group Forecasts Strong Price Appreciation for Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals (LON:HIK) had its price objective raised by Jefferies Financial Group from GBX 1,870 to GBX 2,025 in a note issued to investors on Tuesday,London Stock Exchange reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group’s price target points to a potential upside of 24.00% from the company’s previous close.

Several other equities research analysts also recently weighed in on HIK. Berenberg Bank raised their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a report on Tuesday, August 11th. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of GBX 2,085.83.

Hikma Pharmaceuticals Stock Performance

Shares of Hikma Pharmaceuticals stock opened at GBX 1,633 on Tuesday. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,187 and a fifty-two week high of GBX 1,865. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The firm has a market capitalization of £3.41 billion, a P/E ratio of 9.02, a P/E/G ratio of 2.38 and a beta of 0.66. The company’s 50 day moving average price is GBX 1,574.60 and its two-hundred day moving average price is GBX 1,460.22.

Insider Buying and Selling

In other Hikma Pharmaceuticals news, insider Tobias Hestler purchased 7,500 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of GBX 1,648 per share, for a total transaction of £123,600. Company insiders own 22.04% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.